The soluble sema domain of the RON receptor inhibits macrophage-stimulating protein-induced receptor activation

Debora Angeloni1, Alla Danilkovitch-Miagkova, Alexei Miagkov

  • 1Laboratory of Immunobiology, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702-1201, USA.

Insights

A soluble sema domain of the RON receptor tyrosine kinase inhibits its signaling. This finding suggests potential therapeutic applications for cancer treatment using this molecule.

Area of Science:

  • Molecular Biology
  • Cell Signaling
  • Cancer Research

Background:

  • RON is a receptor tyrosine kinase involved in cell growth and survival.
  • Macrophage-stimulating protein (MSP) is the ligand that activates RON.
  • RON's structure includes extracellular sema, PSI, and immunoglobulin-like domains.

Purpose of the Study:

  • To investigate the function of the RON receptor's sema domain.
  • To determine if a soluble sema domain fragment can inhibit RON signaling.
  • To explore therapeutic potential of the RON sema domain in cancer.

Main Methods:

  • Generated a soluble, secreted molecule representing the sema domain of RON (ron-sema).
  • Assessed the effect of ron-sema on ligand-induced RON activation and signaling.
  • Evaluated the impact of ron-sema on the growth of MSP-responsive cancer cells in vitro.

Main Results:

  • The soluble ron-sema molecule demonstrated a dominant negative effect on RON activation.
  • Ron-sema inhibited RON-dependent signaling pathways and cellular responses.
  • Ron-sema suppressed the growth of MSP-responsive cancer cells, indicating therapeutic potential.

Conclusions:

  • The sema domain of RON plays a role in ligand binding.
  • Ron-sema acts as an inhibitor of RON signaling.
  • Ron-sema represents a potential therapeutic agent for MSP-dependent cancers, possibly via gene therapy.

Related Concept Videos

Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...